Delaware Court Dismisses Tesaro Breach Claim Against AnaptysBio
ANAB has more than doubled off its 52-week low of $11.402.
Summary
The Delaware Chancery Court has dismissed an anticipatory breach claim brought by Tesaro against AnaptysBio. This is a positive development for AnaptysBio, as it removes a potential legal overhang and associated financial liabilities or litigation costs. While the specific financial magnitude of the claim was not disclosed, the resolution of legal disputes generally reduces uncertainty and risk for a company. This news follows the company's recent completion of its biopharma spin-off, and investors will likely view this as another step in streamlining operations and reducing non-core risks.
At the time of this announcement, ANAB was trading at $53.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $11.40 to $55.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.